Top

Annals of Surgical Oncology

Published in:

01-10-2007 | Gastrointestinal Oncology

Expression of Human Leukocyte Antigen G (HLA-G) Correlates with Poor Prognosis in Gastric Carcinoma

Authors: Shang-mian Yie, Hong Yang, Shang-rong Ye, Ke Li, Dan-dan Dong, Xin-mei Lin

Published in: Annals of Surgical Oncology | Issue 10/2007

Abstract

Objective

We had previously demonstrated that human leukocyte antigen G (HLA-G) was expressed in a majority of primary colorectal carcinomas and that the detection of HLA-G expression had a strong and independent prognostic value for that cancer. Currently, we investigate whether or not HLA-G is also expressed in patients with gastric carcinoma and whether the expression has any clinical application value.

Methods

The expression of HLA-G was investigated immunohistochemically in 160 patients with gastric carcinoma. The correlation between HLA-G status and various clinicopathological parameters was analyzed with the levels of HLA-G expression used to compare the survival length amongst patients.

Results

HLA-G protein expression was observed in 71% (113 of 160) of the primary site of gastric carcinomas, but not in the normal stomach tissues. HLA-G expression in the tumors was significantly correlated with the tumor location, histological grade, depth of invasion, lymph nodal metastasis, clinical stages of the disease, and host immune response (P = .012, .008, .001, .038, .030, and .016, respectively). Patients with HLA-G positive tumors had a significantly shorter survival time than those patients with tumors that were HLA-G negative (P = .001). As well, in multivariate analysis, HLA-G demonstrated an independent prognostic factor (P = .0001, relative risk 9.08; 95% confidence interval, 3.44–24.0).

Conclusions

Overall, our results indicated that the expression of HLA-G is a characteristic feature of gastric carcinoma and that immunostaining by anti-HLA-G antibody may be a potentially useful prognostic indicator.

Tanaka K, Yoshioka T, Bieberich C, et al. Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. Ann Rev Immunol 1988; 6:359–80CrossRef

Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanism, functional significance and clinical relevance. Immunol Today 1995; 16:487–94PubMedCrossRef

Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18:89–95PubMedCrossRef

Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 1999; 5:178–86PubMedCrossRef

Seliger B, Abken H, Ferrone S. HLA-G and MIC expression in tumors and their role in anti-tumor immunity. TRENDS in Immunol 2003; 24:82–7CrossRef

LeMaoult J, Le Discorde M, Rouas-Freiss N, et al. Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens 2003: 62: 273–84PubMedCrossRef

Singer G, Kurman RJ, McMaster MT, et al. HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am J Surg Pathol 2002; 26:914–20PubMedCrossRef

Ibrahim EC, Aractingi S, Allory Y, et al. Analysis of HLA antigen expression in benign and malignant melanocytic lesions reveals that upregulation of HLA-G expression correlates with malignant transformation, high inflammatory infiltration and HLA-A1 genotype. Int J Cancer 2004; 108:243–50CrossRef

Bukur J, Rebmann V, Grosse-Wilde H, et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 2003; 63:4107–11PubMed

10.

Urosevic M, Kurrer MO, Kamarashev J, et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade human histology, leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 2001; 159:817–24PubMed

11.

Lefebvre S, Antoinc M, Uzan S, et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 2002; 196:266–74PubMedCrossRef

12.

Urosevic M, Willers J, Mueller B, et al. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 2002; 99:609–17PubMedCrossRef

13.

Davidson B, Elstrand MB, McMaster MT, et al. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol 2005; 96:42–7PubMedCrossRef

14.

Barrier BF, Kendall BS, Sharpe-Timms K, et al. Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. Gynecol Oncol 2006; 103:25–30PubMedCrossRef

15.

Hansel DE, Rahmanb A, Wilentz RE, et al. HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract Int J Gastrointest Cancer 2005; 35:15–24PubMedCrossRef

16.

Fukushima Y, Oshika Y, Nakamura M, et al. Increased expression of human histocompatibility leukocyte antigen-G in colorectal cancer cells. Int J Mo Med 1998; 2:349–51

17.

Ishigami S, Natsugoe S, Miyazono F, et al. HLA-G expression in gastric cancer. Anticancer Res 2006: 2467–72

18.

Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol 2003; 81:199–252PubMedCrossRef

19.

Le Discorde M, Moreau P, Sabatier P, et al. Expression of HLA-G in human cornea, an immune-privileged tissue. Hum Immunol 2003; 64:1039–44PubMedCrossRef

20.

Ito T, Ito N, Saathoff M, et al. Immunology of the human nail apparatus: the nail matrix is a site of relative immune privilege. J Invest Dermatol 2005; 125:1139–48PubMedCrossRef

21.

Cirulli V, Zalatan J, McMaster M, et al. The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLA-G. Diabetes 2006; 55:1214–22PubMedCrossRef

22.

Bainbridge DR, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4 (+) T-lymphocytes. J Reprod Immunol 2000; 48:17–26PubMedCrossRef

23.

Lila N, Rouas-Freiss N, Dausset J, et al. Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci USA 2001; 98:12150–5PubMedCrossRef

24.

Le Gal FA, Riteau B, Sedlik C, et al. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 1999; 11:1351–6PubMedCrossRef

25.

Riteau B, Menier C, Khalil-Daher I, et al. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol 2001; 13:193–201PubMedCrossRef

26.

Rebmann V, Regel J, Stolke D, et al. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol 2003; 13:371–7PubMedCrossRef

27.

Sebti Y, Le Friec G, Pangault C, et al. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol 2003; 64:1093–101PubMedCrossRef

28.

Nuckel H, Rebmann V, Durig J, et al. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 2005; 105:1694–8PubMedCrossRef

29.

Ugurel S, Rebmann V, Ferrone S, et al. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer 2001; 92:369–76PubMedCrossRef

30.

Singer G, Rebmann V, Chen YC, et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 2003; 9:4460–4PubMed

31.

Ye SR, Yang H, Li K, et al. Human leukocyte antigen G (HLA-G) expression: as a significant prognostic indicator for patients with colorectal cancer. Modern Pathol 2007; 20:375–83CrossRef

32.

Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: the global picture. Eur J Cancer 2001; 37(suppl):4–66CrossRef

33.

Yang L, Parkin DM, Ferlay J, et al. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 2005; 14:243–50PubMedCrossRef

34.

Fenogilo-Preiser C, Carneiro F, Correa P, et al. Gastric carcinoma. In: Hamilton S, Aaltonin L (ed.) Pathology and Genetics. Tumors of the Digestive System, vol. 1, Lyon, France: Lyon Press, 2000:37–52

35.

Menier C, Saez B, Horejsi V, et al. Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol 2003; 64:315–26PubMedCrossRef

36.

Alexander J, Watanabe T, Wu TT, et al. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 2001; 158:527–35PubMed

37.

Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. Lyon: IARC Press, Cited April 15, 2005. Available from: URL: http://wwwdep.iarc.fr/

38.

Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol 2006; 12:17–20PubMed

39.

Crawford J. The gastrointestinal tract. In: Robbins SLCR, Kumar V, Schoen FJ (ed.) Pathologic Basis of Disease. Philadelphia: WB Saunders Co., 1994:755–83

40.

Pinto-de-sousa J, David L, Seixas M, et al. Clinicopathologic profiles and prognosis of gastric carcinoma from the cardia, fundus/body and antrum. Dig Surg 2001; 18:102–10PubMedCrossRef

41.

Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 2004; 101:3–27PubMedCrossRef

42.

Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Stewart M, Hamilton SM. Gastric Adenocarcinoma: Review and Considerations for Future Directions. Ann Surg 2005; 241:27–39PubMed

43.

Rouas-Freiss N, Philippe Moreau P, et al. HLA-G Proteins in Cancer: Do They Provide Tumor Cells with an Escape Mechanism? Cancer Res 2005; 65:10139–44PubMedCrossRef

44.

Malmberg KJ, Levitsky V, Norell H, et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism J Clin Invest 2002; 110:1515–23PubMedCrossRef

Title: Expression of Human Leukocyte Antigen G (HLA-G) Correlates with Poor Prognosis in Gastric Carcinoma
Authors: Shang-mian Yie
Hong Yang
Shang-rong Ye
Ke Li
Dan-dan Dong
Xin-mei Lin
Publication date: 01-10-2007
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 10/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-007-9464-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Expression of Human Leukocyte Antigen G (HLA-G) Correlates with Poor Prognosis in Gastric Carcinoma

Abstract

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2007

Young Age Influences Treatment but not Outcome of Colon Cancer

Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors

Sentinel Lymph Node Biopsy Performed After Neoadjuvant Chemotherapy is Accurate in Patients with Documented Node-Positive Breast Cancer at Presentation

Outcomes of Pheochromocytoma Management in the Laparoscopic Era

Pelvic Lymph Node Dissection Is Beneficial in Subsets of Patients with Node-positive Melanoma

Prescribing Patterns of Surgical Oncologists: Are We Surgeons, Oncologists, or Both?